(Q45330828)

English

Correlation between the biological and therapeutic effects of interferon-alpha in low-grade nodular non-Hodgkin's lymphoma: Lack of in vivo down-regulation and reduced affinity of IFN-α receptors in unresponsive patients

scientific article published on January 1, 1991

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 December 2017

Correlation between the biological and therapeutic effects of interferon-alpha in low-grade nodular non-Hodgkin's lymphoma: Lack of in vivo down-regulation and reduced affinity of IFN-α receptors in unresponsive patients (English)

reason for preferred rank

most precise value

1 reference

10.1016/0145-2126(91)90092-8

https://api.crossref.org/works/10.1016/0145-2126(91)90092-8

3 December 2022

Correlation between the biological and therapeutic effects of interferon-alpha in low-grade nodular non-Hodgkin's lymphoma: lack of in vivo down-regulation and reduced affinity of IFN-alpha receptors in unresponsive patients (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1826751

3 December 2022

1 reference

10.1016/0145-2126(91)90092-8

https://api.crossref.org/works/10.1016/0145-2126(91)90092-8

3 December 2022

author name string

C. Billard

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1826751

3 December 2022

D. Ferbus

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1826751

3 December 2022

R. A. Diez

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1826751

3 December 2022

J. P. Kolb

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1826751

3 December 2022

C. Mathiot

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1826751

3 December 2022

C. Belanger

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1826751

3 December 2022

G. Auzanneau

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1826751

3 December 2022

B. Varet

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1826751

3 December 2022

E. Falcoff

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1826751

3 December 2022

J. Dumont

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1826751

3 December 2022

language of work or name

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1826751

3 December 2022

publication date

1 January 1991

1 reference

Europe PubMed Central

13 December 2017

full work available at URL

https://api.elsevier.com/content/article/PII:0145212691900928?httpAccept=text/xml

1 reference

10.1016/0145-2126(91)90092-8

https://api.crossref.org/works/10.1016/0145-2126(91)90092-8

3 December 2022

https://api.elsevier.com/content/article/PII:0145212691900928?httpAccept=text/plain

1 reference

10.1016/0145-2126(91)90092-8

https://api.crossref.org/works/10.1016/0145-2126(91)90092-8

3 December 2022

Leukemia Research

1 reference

Europe PubMed Central

13 December 2017

15

1 reference

Europe PubMed Central

13 December 2017

2-3

1 reference

Europe PubMed Central

13 December 2017

121-128

1 reference

Europe PubMed Central

13 December 2017

Clinical overview of alpha interferon. Studies and future directions

2

1 reference

10.1016/0145-2126(91)90092-8

https://api.crossref.org/works/10.1016/0145-2126(91)90092-8

3 December 2022

The evolving role of alpha interferon in the treatment of malignancies

3

1 reference

10.1016/0145-2126(91)90092-8

https://api.crossref.org/works/10.1016/0145-2126(91)90092-8

3 December 2022

Interferon receptors

4

1 reference

10.1016/0145-2126(91)90092-8

https://api.crossref.org/works/10.1016/0145-2126(91)90092-8

3 December 2022

Action of interferon-alpha on hairy cell leukemia: expression of specific receptors and (2'-5')oligo (A) synthetase in tumor cells from sensitive and resistant patients.

5

1 reference

10.1016/0145-2126(91)90092-8

https://api.crossref.org/works/10.1016/0145-2126(91)90092-8

3 December 2022

Treatment of hairy cell leukemia with recombinant alpha interferon: II. In vivo down-regulation of alpha interferon receptors on tumor cells

6

1 reference

10.1016/0145-2126(91)90092-8

https://api.crossref.org/works/10.1016/0145-2126(91)90092-8

3 December 2022

Down-regulation of peripheral blood cell interferon receptors in chronic myelogenous leukemia patients undergoing human interferon (HuIFN alpha) therapy

8

1 reference

10.1016/0145-2126(91)90092-8

https://api.crossref.org/works/10.1016/0145-2126(91)90092-8

3 December 2022

Sequential therapy with recombinant interferons gamma and alpha in patients with unfavorable prognosis of chronic myelocytic leukemia: clinical responsiveness to recombinant IFN-alpha correlates with the degree of receptor down-regulation

10

1 reference

10.1016/0145-2126(91)90092-8

https://api.crossref.org/works/10.1016/0145-2126(91)90092-8

3 December 2022

Biochemistry of Interferons and Their Actions

11

1 reference

10.1016/0145-2126(91)90092-8

https://api.crossref.org/works/10.1016/0145-2126(91)90092-8

3 December 2022

INTERFERONS IN CANCER THERAPY: A REAPPRAISAL

12

1 reference

10.1016/0145-2126(91)90092-8

https://api.crossref.org/works/10.1016/0145-2126(91)90092-8

3 December 2022

Treatment of hairy cell leukemia with recombinant alpha interferon: I. Quantitative study of bone marrow changes during the first months of treatment

17

1 reference

10.1016/0145-2126(91)90092-8

https://api.crossref.org/works/10.1016/0145-2126(91)90092-8

3 December 2022

2–5A synthetase activity does not increase in interferon-resistant friend leukemia cell variants treated with α/β interferon despite the presence of high-affinity interferon receptor sites

18

1 reference

10.1016/0145-2126(91)90092-8

https://api.crossref.org/works/10.1016/0145-2126(91)90092-8

3 December 2022

Specific high-affinity binding of 125I-labeled mouse interferon to interferon resistant embryonal carcinoma cells in vitro

19

1 reference

10.1016/0145-2126(91)90092-8

https://api.crossref.org/works/10.1016/0145-2126(91)90092-8

3 December 2022

Heterogeneity of CLL: high CD23 antigen and alpha IFN receptor expression are features of favourable disease and of cell activation

20

1 reference

10.1016/0145-2126(91)90092-8

https://api.crossref.org/works/10.1016/0145-2126(91)90092-8

3 December 2022

Identifiers

10.1016/0145-2126(91)90092-8

1 reference

Europe PubMed Central

13 December 2017

1 reference

Europe PubMed Central

13 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45330828&oldid=1783569095"